CBT
BIB icon

Capital Bank & Trust’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Capital Bank & Trust’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-232
Closed -$11K – 329
2020
Q1 		$11K Buy
+232
New +$12.9K ﹤0.01% 537

Other funds holding BIB

GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
SW
SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Capital Bank & Trust's BIB Position: Q2 2020 in Review

Capital Bank & Trust sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2020, closing a stake of 232 shares — an estimated $11K sold.

Capital Bank & Trust first reported a position in BIB in Q1 2020 and held it in 1 quarter. The position peaked at $11K in Q1 2020. 27 funds tracked by Wall St. Rank hold BIB as of Q2 2020.

  • Capital Bank & Trust reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 232 ProShares Ultra NASDAQ Biotechnology shares in Q2 2020, an estimated $11K.
  • Capital Bank & Trust first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2020 and held it in 1 quarter.
  • Capital Bank & Trust's ProShares Ultra NASDAQ Biotechnology position peaked at $11K in Q1 2020.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.